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ighly active antiretroviral therapy (HAART) 
has dramatically reduced morbidity and 
mortality associated with acquired immu-
nodeficiency syndrome (AIDS), and human immunodefi-
ciency virus (HIV) infection has become a chronic and man-
ageable disease. Paralleling increased life expectancy, HIV-
infected subjects may present many comorbidities, most 
notably cardiovascular diseases, and recent studies have 
identified an increased prevalence of traditional coronary 
risk factors in these patients. Moreover, additional investi-
gations suggest that HIV itself may independently favour 
premature atherosclerosis, and antiretroviral agents also 
could directly or indirectly play a role in the atherosclerotic 
process. Dyslipidaemia, insulin resistance, inflammation, 
and fat redistribution are all likely to contribute to this 
pathogenetic pathway, and these abnormalities may be 
interrelated and due to either HIV infection, or the related 
inflammatory syndrome, or HAART-associated toxicity. 
Appropriate screening and assessment of cardiovascular 
risk and intensive strategies for prevention of cardiovas-
cular events are suitable in HIV-infected patients, includ-
ing lifestyle measures, switching antiretroviral drugs, and 
pharmacologic therapy of lipid and glucose metabolism 
alterations. This article reviews the correlation between 
HIV infection and myocardial infarction, and discusses the 
most appropriate clinical management of cardiovascular 
risk among HIV-positive individuals.
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he introduction of highly active antiret-
roviral therapy (HAART) has led to a dra-
matic decrease in morbidity and mortality 
associated with the human immunodeficiency virus (HIV) 
infection, with mortality declining from 20-30 deaths per 
100 person-years before 1995, up to to 2-5 deaths per 
100 person-years after 19971-3, with these figures con-
tinuing to decrease in recent years.
Since new antiretroviral regimens have led to a notable 
extension of life expectancy in HIV-positive patients, ques-
tions related to comorbidities and long-term adverse ef-
fects of HAART have recently emerged. An increasing 
concern is mounting particularly about the increased risk 
of coronary artery disease in HIV-infected subjects, as re-
cently described in two large prospective studies4,5. Owing 
to the effectiveness of HAART and the increasing age of 
patients, more than 50% of deaths in HIV-positive popu-
lation are now from causes other than acquired immune 
deficiency syndrome (AIDS), and the percentage of non-
AIDS related deaths continues to increase. Particularly, the 
most frequent non-AIDS-associated causes of deaths are 
comparable in recent surveys and include malignancies, 
chronic liver disease and cardiovascular disease6-8.
Several of the traditional risk factors for coronary artery 
disease are frequently reported in HIV-positive individuals, 
including factors related to the patients’ lifestyle (such as 
cigarette smoking and drug addiction), and factors associ-
ated with HIV infection itself and antiretroviral drugs (such 
as dyslipidaemia, insulin resistance, diabetes mellitus, cen-
tral adiposity, arterial hypertension, and direct effects of 
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the virus or antiretroviral agents on the vascular system). 
Moreover, some data suggest that endothelial dysfunc-
tion, impaired fibrinolysis, and increased inflammation 
are more common in HIV-positive patients than in general 
population, and may contribute to an increased cardio-
vascular risk9,10. At the same time, carotid intimal-media 
thickness and coronary calcification assessments suggest 
increased incidence of atherosclerotic disease and prema-
ture occurrence of arterial atherosclerotic lesions among 
HIV-infected individuals11,12.
To the best of our knowledge, HIV and HAART may con-
tribute to an increased risk of cardiovascular diseases 
in three principal ways: (1) HIV infection can identify 
a subgroup of the general population with a greater 
prevalence of traditional risk factors unrelated to HIV 
or HAART (eg, male sex, advancing 
age, higher smoking rate, alcohol-
ism or drug addict); (2) HIV infection 
and HAART can indirectly favour the 
occurrence of traditional risk factors 
(eg, hyperlipidaemia, insulin resist-
ance, diabetes mellitus, fat redis-
tribution, or hypertension); (3) HIV 
and HAART can directly affect the 
pathogenesis of atherosclerotic dis-
ease (eg, through inflammation and 
endothelial dysfunction)13.
The body of our knowledge sug-
gest that all three above-mentioned 
mechanisms are plausible and con-
temporaneously affecting the risk 
of coronary artery disease in HIV-
infected subjects. However, experi-
mental and clinical data are often 
conflicting still today, and several 
questions remain as to the detec-
tion, pathogenesis, prevention and 
treatment of cardiovascular diseases 
and related risk factors. This review 
will assess the most recent literature 
data in order to explain next essen-
tial questions in HIV-positive popula-
tion: (1) incidence of myocardial inf-
arction and related risk factors; (2) incidence of premature 
atherosclerosis and related risk factors; (3) pathogenetic 
role of HIV infection; (4) pathogenetic role of antiretro-
viral therapy; (5) screening and diagnosis; (6) treatment 
and prevention. A more straightforward understanding 
of the cardiovascular complications associated with HIV 
disease is also advisable in order to design the most ad-
equate clinical trials and to define the most appropriate 
guidelines for the clinical management of these long-
term complications.
Myocardial infarction in hiv-infected patients
The first cases of acute myocardial infarction in HIV-posi-
tive individuals under combination antiretroviral treatment 
have been described in early year 1998. These initial case 
reports suggested an increased frequence of cardiovas-
cular diseases in HIV-infected patients receiving combina-
tion antiretroviral therapy, raising the question of the as-
sociation between cardiovascular complications and new, 
potent therapies including protease inhibitors (PIs)14-16. 
Subsequently, some retrospective and prospective studies 
have shown that the incidence of myocardial infarction 
in HIV-positive subjects treated with antiretroviral therapy 
tends to be higher than in the general population, par-
ticularly in those receiving a PI-based treatment17. How-
ever, reports from large observational studies demonstrate 
that considerable controversy exists until now about the 
association of HAART, particularly PI-based combinations, 
with increased incidence of coronary heart disease risk. 
The most large studies investigating incidence of cardio-
vascular events in HIV-positive subjects and their associa-
tion with HAART are summarized in Table 1.
Jütte et al. retrospectively assessed the incidence of myo-
cardial infarction among 1,324 HIV-infected individuals 
receiving antiretroviral therapy (951 without PI and 373 
with PIs), and followed-up between 1990 and 1998. The 
myocardial infarction rate was significantly greater in PI-
treated than in PI-untreated subjects (1.06 and 0.21 per 
100 patient-years, respectively), showing a five-fold in-
creased risk of coronary events in PI-treated patients com-
pared with untreated controls18. 
Rickerts et al. performed a retrospective analysis of a co-
hort of 4,993 HIV-positive patients treated with different 
antiretroviral treatment strategies, between the years 
1983 and 1998. The incidence of coronary heart disease 
increased significantly in this cohort after the introduc-
tion of HAART. Particularly, the incidence of myocardial 
infarction increased from 0.86 (in the period 1983-86) 
Author, year 
[reference]
Type 
of 
study
N. of 
patients
Years of 
study
Events
N. of 
events
Event rate 
per 1000 
person/years
HIV+ group
Increased 
risk of CVD 
associated 
with CART
Jütte, 1999 [18] R 1,324 1990-1998 MI 5 10.6 Yes (PIs)
Holmberg, 2002 [4] P 5,672 1993-2002 21 1.42 Yes (PIs)
DAD Study Group 
[5, 24, 31]
P 33,347 1999-2007 MI 517 3.5
Yes (PIs, 
ABC, ddI)
Rickerts, 2000 [19] R 4,993 1983-1998 MI 29 3.41 Yes
Klein, 2002 [20] R 4,159 1996-2001 CVD 47 4.3 No
Currier, 2003 [21] R 28,513 1994-2000 CVD 294 4.12 Yes
Mary-Krause, 2003 
[22]
R 34,976 1996-1999 MI 49 4.9 Yes (PIs)
Escaut, 2003 [23] R 840 1997-2002 MI 17 5.9 Yes
Obel, 2007 [25] P 3,953 1995-2004 MI 11 2.3 Yes
Iloeje, 2005 [26] P 7,542 1996-2003 CVD 112 11.5 Yes (PIs) 
Bozzette, 2003 [28] R 36,766 1993-2001 CVD 410 5 No
Triant, 2007 [30] P 3,851 1996-2004 MI 189 11.13 No
SMART Study, 
2008 [29, 32]
P 2,752 2004-2007 CVD 112 4.3 Yes (ABC)
Brothers, 2009 [33] P 14,174 1997-2004 MI 18 2.3
No 
association 
with ABC
HIV, human immunodeficiency virus; CVD, cardiovascular diseases; CART, combination antiretroviral therapy; R, 
retrospective; P, prospective; MI, myocardial infarction; PIs, protease inhibitors; ABC, abacavir; ddI, didanosine
Table 1. Retrospective and prospective studies evaluating the relationship between risk of 
cardiovascular events and use of combination antiretroviral therapy.
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to 3.41 per 1,000 patient-years (in the period 1995-98) 
(p=0.002). Increased age (higher than 40 years), homo- or 
bisexual mode of HIV transmission, previous AIDS diag-
nosis, and previous HAART were significantly associated 
with myocardial infarction in univariate analysis, and in-
creased age and previous HAART remained significantly 
associated with coronary heart disease also in a multiple 
regression model19.
Klein et al. examined data from the Kaiser Permanente 
Medical Care Program of Northern California to compare 
hospitalization rates for coronary heart disease among 
HIV-infected and HIV-uninfected subjects, before and 
after PI introduction. This data set identified 4,159 HIV-
positive patients aged 35 to 64 years, followed from 1996 
up to 2003, with a median total follow-up of 4.1 years. 
The age-adjusted coronary heart disease hospitalization 
rate was significantly higher in HIV-positive members than 
in HIV-negative ones (6.5 vs 3.8; p=0.003), and the dif-
ference in the myocardial infarction rate also was higher 
(4.3 vs 2.9; p=0.07). However, the age-adjusted rate of 
myocardial infarction in patients receiving PIs was not 
statistically greater than in patients not receiving PIs (4.0 
vs 3.4 per 1,000 patient-years). Similarly, hospitalization 
rates for cardiovascular diseases were not significantly dif-
ferent before versus after PIs (6.2 vs 6.7 events per 1,000 
patient-years), or before versus after antiretroviral therapy 
(5.7 vs 6.8)20.
Currier et al. reviewed administrative claims data for the 
HIV-positive and HIV-negative individuals from the Califor-
nia Medicare population, and investigated the incidence 
and the relative risk for coronary heart disease using log-
linear regression analyses between two groups. The in-
cidence of cardiovascular events among young men (up 
to age 34) and women (up to age 44) was significantly 
higher in HIV-positive compared with HIV-negative per-
sons. Moreover, the covariate-adjusted relative risk for the 
development of coronary heart disease in subjects receiv-
ing antiretroviral drugs compared with those not receiving 
medications was 2.06 (p<0.001) in HIV-infected patients 
aged 18-33 years. Notably, there were no statistically sig-
nificant associations between antiretroviral exposure and 
cardiovascular complications in other age groups21.
Mary-Krause et al. assessed the incidence of myocardial 
infarction among 34,976 HIV-infected male patients be-
longing to the French Hospital Database on HIV, who were 
followed up for a median of 33 months between years 
1996 and 1999. Myocardial infarction was diagnosed in 
60 men among 88,029 person-years, including 49 cases 
among men receiving PIs. The exposure to PIs was associ-
ated with a higher risk of cardiovascular diasease, and the 
myocardial infarction rates increased in relation to dura-
tion of PI therapy (10.8 events per 10,000 person-years 
in men with <18 months PI use; 33.8 events per 10,000 
person-years in those with >30 months PI use). The stand-
ardized morbidity ratios relative to the French general 
male population were 0.8 for men exposed to PI for <18 
months, 1.5 for men exposed for 18-29 months, and 2.9 
for men exposed for over 30 months. These results have 
pointed to a duration-related effect relationship between 
PI and myocardial infarction, with a greater incidence of 
this cardiac complication among patients exposed to PI for 
18 months or more22.
Escaut et al. evaluated retrospectively the incidence of 
coronary artery disease among 840 HIV-positive individu-
als followed-up for 5 years. Incidence of coronary events 
was 5.9 per 1,000 person-years and a greater risk of these 
complications was found to be associated with HAART, 
metabolic disturbances, and a higher prevalence of to-
bacco smoking23.
Moreover, recent prospective studies involving large co-
horts of HIV-infected patients have documented an in-
creased incidence of myocardial infarction and cerebrov-
ascular diseases in association with a prolonged exposure 
to combination antiretroviral therapies, even if the abso-
lute risk of cardiovascular events remains low, and should 
be balanced against the remarkable benefits from HAART 
in terms of improvement in immune function and related 
morbidity and mortality. 
Prospective studies have recently been published which 
were specifically designed to evaluate the incidence of 
cardiovascular diseases in HIV-positive population. Pro-
spective observational cohorts with more systematic as-
sessment of cardiovascular disease risk factors and valida-
tion of outcomes provide more insight into the epidemiol-
ogy of cardiac complications in the HAART era, and are 
certainly more generalizable.
In the HIV Outpatient Study (HOPS), Holmberg et al. de-
scribed 21 cases of myocardial infarction among 5,672 
patients from nine United States HIV Clinics during 
17,712 patient-years of follow-up (performed between 
years 1993 and 2002). The frequency of myocardial inf-
arction increased after the introduction of PIs in the year 
1996; this cardiac complication occurred in 19 patients 
on PIs (1.42 per 10,000 patient-years) and in two subjects 
not on PIs (0.46 per 10,000 patient-years; odds ratio=7.1). 
In multivariate Cox proportional hazards models adjusted 
for smoking, gender, age, diabetes mellitus, hypertension, 
and dyslipidemia, the hazard ratio was 6.5, suggesting 
that use of PIs is associated with increased risk of myocar-
dial infarction in subjects with HIV infection4.
The Data Collection on Adverse Events of Anti-HIV Drugs 
(DAD) Study is a prospective, observational study of 11 
previously established cohorts comprising 23,468 HIV-in-
fected patients followed in 21 countries in Europe, United 
States and Australia. During this study, a total of 126 epi-
sodes of myocardial infarction were diagnosed, leading to 
a crude incidence rate of 3.5 per 1,000 patient-years. The 
authors showed that the incidence of myocardial infarc-
tion increased significantly with increasing exposure to 
combination antiretroviral therapy, and the adjusted risk 
rate per year of exposure ranged from 0.32 for no HAART 
use to 2.93 for >6 years of HAART use. This suggested that 
during the first four to six years of combination antiretro-
viral treatment there was approximately a 26% increase in 
the relative risk of suffering from a myocardial infarction, 
but the absolute risk of coronary events was low and must 
be balanced against the remarkable benefits from antiret-
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roviral therapy. On the other hand, the incidence rate of 
myocardial infarction did not exceed that of what should 
be expected from the background population given the 
same cluster of cardiovascular risk factors. Other factors 
that also independently predicted myocardial infarction 
in the DAD study were increased age, current or past 
smoking, previous cardiovascular diseases, male sex, hy-
percholesterolaemia, hypertriglyceridaemia, and diabetes 
mellitus5. Increased exposure to PIs was associated with 
an increased risk of myocardial infarction, which is partly 
explained by dyslipidaemia, while no evidence of such an 
association for non-nucleoside analogues was found24.
A case-control survey involving 3,953 HIV-infected pa-
tients and 373,856 persons in a population-based control 
group showed that after initiation of HAART the cardio-
vascular risk was significantly higher among HIV-infected 
subjects than among control subjects, but the relative risk 
did not further increase, and were stable in the initial 8 
years of antiretroviral treatment25. 
Iloeje et al. estimated the risk of cardiovascular disease 
events with PI exposure in a prospective observational 
study involving a cohort of 7,542 HIV-infected patients 
(whose 77% exposed to PIs) followed-up between 1996 
and 2003. The study population was derived from the 
Centers for Disease Control and Prevention HIV Outpa-
tient Study (HOPS) and additional physician offices and 
Clinics funded by the sponsoring agency, Cerner Corpo-
ration. The median duration of follow-up was 3.5 years 
and 2 years for the PI and non-PI groups, respectively, and 
the median PI exposure in the first group was 1.7 years. 
The incidence of cardiovascular complications was signifi-
cantly higher in subjects exposed to PIs: a total of 127 
cardiovascular events were observed, with 112 in the PI 
group for an adjusted event rate of 9.8 per 1,000 person-
years of follow-up, and 15 in the nonPI group for an ad-
justed event rate of 6.5 per 1,000 person-years of follow-
up (p=0.0008). In the multivariate analyses, cumulative PI 
therapy for >60 days was associated with an increased risk 
of cardiovascular diseases and the cardiovascular event 
rates were also higher in the PI group among patients in 
the 35 to 65-year-old subset. Other independent risk fac-
tors were current or past smoking, hypertension, diabetes 
mellitus, and pre-existing cardiovascular diseases26.
Kaplan et al. estimated the predicted risk of coronary 
heart disease among 2,386 HIV-infected and 1,675 HIV-
uninfected patients on the basis of age, sex, lipid and 
blood pressure levels, presence of diabetes mellitus, and 
smoking. Among HIV-positive persons, antiretroviral ther-
apy exposure, increased body mass index and low income 
level were associated with increased predicted risk of cor-
onary disease27.
In contrast, in a large retrospective study using the Vet-
erans’ Affairs Database (which included 36,766 patients 
followed up for an average of 40 months, between years 
1993 and 2001), Bozzette et al. showed that PI therapy 
was not associated with an increased risk of coronary heart 
disease. Patient-level regression analyses indicated that 
there was no relation between the administration of nu-
cleoside analogues, non-nucleoside analogues, or PIs and 
the hazard of cardiovascular or cerebrovascular events. On 
the contrary, in this study the use of antiretroviral therapy 
was associated with a decreased risk of death from any 
cause. However, the median duration of exposure to PIs 
was only 16 months, and the true cardiovascular disease 
rate may have been underestimated, because many pa-
tients with acute myocardial infarction may not have been 
admitted to Veterans’ Affairs hospitals28.
Another important concern about the risk of coronary 
events in HIV-positive subjects has emerged from the Strat-
egies for Management of Antiretroviral Therapy (SMART) 
study. This trial randomized 5,472 HIV-infected patients 
with CD4+ cell counts above 350 cells/mm3 to intermit-
tent antiretroviral therapy versus continuous antiretroviral 
therapy, and compared clinical outcomes. A total of 477 
participants were evaluated during a mean follow-up of 
18 months and the hazard ratio for risk of cardiovascular 
diseases for patients allocated to discontinuous therapy 
versus continuous therapy was 1.57. Although total and 
LDL cholesterol levels were usually reduced during discon-
tinuations of HAART, the reasons for this higher cardiovas-
cular risk associated with intermittent therapy are unclear 
still today29.
Triant et al.30 compared myocardial infarction rates (based 
on hospital claims data) among 3,851 HIV-infected sub-
jects and 1,044,589 HIV-uninfected controls receiving 
longitudinal care in two tertiary care hospitals between 
1996 and 2004. Incidence of myocardial infarction and 
prevalence of cardiovascular risk factors (hypertension, 
diabetes, and dyslipidaemia), were found to be higher in 
HIV-positive compared with HIV-negative persons, partic-
ularly among women.
Concern has also been raised regarding the potential car-
diovascular risk associated with nucleoside reverse tran-
scriptase inhibitors (NRTIs), and particularly with abacavir. 
The DAD study group used Poisson regression models to 
assess the relation between recent and past use of NRTIs 
and occurrence of myocardial infarction in 33,347 pa-
tients with 157,912 person-years of follow-up. Recent 
(within 6 months) or current, but not cumulative or past 
use (last use > 6 months) of abacavir or didanosine was 
associated with an increased risk of myocardial infarction 
(relative risk, 1.9 with abacavir and 1.49 with didanosine). 
The excess risk did not seem to be explained by underlying 
established cardiovascular risk factors, but the heightened 
risk of myocardial infarction with recent abacavir or di-
danosine exposure was accentuated in subjects with pre-
existing risk factors for coronary artery disease31. A second 
study confirmed these data. An analysis of 2,752 patients 
assigned to the continuous antiretroviral therapy arm of 
the SMART study showed that current use of abacavir was 
associated with an excess risk of cardiovascular disease 
compared with other NRTIs (relative risk for myocardial 
infarction, 4.3). Even in this study, the highest risk was 
concentrated in individuals with five or more known car-
diovascular risk factors32.
In contrast to these two observational sudies, data from 
GlaxoSmithKline-sponsored trials found no increased car-
diovascular risk in patients recently exposed to abacavir. 
Revista Latinoamericana de Hipertensión. Vol. 4 - Nº 4, 2009
90
In a recent report, data from 52 clinical trials including 
14,174 HIV-positive adults on HAART (9,502 abacavir re-
cipients compared with 4,672 participants who did not 
receive abacavir) for at least 24 weeks were analysed. In 
this pooled summary, myocardial infarction rates were 
comparable among subjects exposed or not to abacav-
ir-containing regimens (incidence of 2.09 and 2.57 per 
1,000 person-years, respectively)33.
Taken together, the above mentioned studies have shown 
that HIV-infected adults appear to have an increased rela-
tive risk of cardiovascular diseases compared with non-HIV 
patients, but they also have noted a higher prevalence of 
conventional cardiovascular risk factors (such as smoking, 
dyslipidaemia, diabetes mellitus, and arterial hypertension) 
in HIV-positive population, and it is often very difficult to 
determine the exact pathogenetic role of HIV infection per 
se, exposure to HAART, and traditional risk factors13.
Moreover, data obtained from retrospective and prospec-
tive studies suggest that a small but significantly increased 
risk exists for myocardial infarction in association with HIV 
infection and combination antiretroviral therapy (and par-
ticularly with PIs, abacavir, and didanosine), regardless of 
traditional risk factors. Although conflicting data exist re-
garding risk of myocardial infarction associated with some 
NRTIs, the magnitude of the increased risk among the 
subset of individuals at high risk of coronary artery disease 
should not be ignored, and alternatives to abacavir and 
didanosine should be considered in persons at higher risk 
for cardiovascular complications. Certainly, data are not 
fully unanimous and larger, prospective studies evaluating 
cardiovascular risks of HIV disease are certainly requested, 
with appropriate design and statistical consideration of 
the effects of HAART and other, concomitant risk factors. 
Premature atherosclerosis in hiv-infected patients
Investigation of subclinical atherosclerosis using evalua-
tion of intima-media thickness and endothelial function 
have led new insights on the pathogenesis of structural 
and functional changes of arterial vessels observed in HIV-
infected subjects. However, contradictory reports have 
been published concluding that HIV infection and antiret-
roviral therapy do or do not promote atherogenesis. 
Endothelial dysfunction, reduced flow-mediated arterial 
dilatation and premature atherosclerotic lesions have been 
reported among HIV-infected patients receiving HAART, 
and newly available data highlight the incidence of car-
diovascular events in this population. However, whether 
the increased cardiovascular risk in HIV-positive subjects is 
due to HIV infection itself, to antiretroviral therapy, or to 
a synergistic interaction between these factors, remains 
to be established. Although both HIV disease and HAART 
are associated with a lipid and glucose profile known to 
increase the risk of coronary and cerebrovascular compli-
cations, these metabolic factors do not fully account for 
the premature atherosclerotic lesions observed in these 
patients, suggesting that other mechanisms or mediators 
might be involved.
The association between antiretroviral therapy and pre-
mature atherosclerosis has been shown in some studies. 
Lai et al.34 evaluated the association between PIs and ac-
celerated atherosclerosis in 98 black adult HIV-infected 
patients aged 25 to 45 years. Subjects taking PIs had sig-
nificantly higher plasma levels of total and LDL cholester-
ol, and those treated with ritonavir, nelfinavir or saquinavir 
were more likely to have a higher coronary artery calcium 
score than those on non-PI regimens.
Maggi et al.11 evaluated 293 HIV-positive subjects, re-
ceiving PIs (n=105) or naive to PI therapy (n=188), by an 
epiaortic vessel colour-Doppler ultrasonography. Vascular 
lesions (including intima-media thickness >1 mm and/or 
atheromatous plaques), were detected in 52.4% of the 
PI-treated patients, while only 14.9% of the PI-naive in-
dividuals presented acquired lesions of the vascular wall. 
Antiretroviral therapy, age, cigarette smoking, and CD4 
T-cell count were the main predictive risk factors for vas-
cular lesions, but the highest significance value was found 
to be linked with the administration of PIs35. Moreover, 
in a study involving 110 HIV-positive patients and 91 
HIV-negative patients, Maggi et al.36 showed that HIV-
infected subjects had a significantly higher number of 
hypoechogenic lesions (not fibrous or calcified), that had 
homogeneous parietal and endoluminal portions along 
with a smooth or slightly irregular surface. Ultrasono-
graphic structure of the epi-aortic lesions in HIV-infected 
patients substantially differed from those of plaques in 
atherosclerotic individuals, although they shared similar 
features with patients affected by arteritis. These authors 
suggested that the pathogenetic mechanism responsible 
for carotid lesions associated with HIV infection may be 
more similar to an inflammatory process than the classical 
atherogenesis36-38.
Jericò et al. investigated the relationship between com-
bination antiretroviral therapy and subclinical carotid 
atherosclerosis according to cardiovascular risk in 132 
HIV-infected patients who underwent a carotid high-res-
olution B-mode ultrasonography. Antiretroviral treatment 
exposure and a 10-year coronary risk estimated >10%, 
were found to be independent variables associated with 
subclinical carotid atherosclerosis12.
Similarly, de Saint Martin et al.39 assessed 154 HIV-infected 
individuals and confirmed the occurrence of premature 
atherosclerosis, which not only correlated with the usual 
risk factors (such as serum triglyceride, cholesterol, and 
glucose levels), but also with the PI exposure, especially 
the use of lopinavir/ritonavir. Moreover, Stein et al.9 dem-
onstrated impaired flow-mediated dilatation of the bra-
chial or carotid artery (an early surrogate marker for en-
dothelial dysfunction and subsequent plaque formation), 
among HIV-positive subjects receiving PIs, in comparison 
with PI-naive patients. 
In a case-control survey involving 292 HIV-positive sub-
jects and 1168 age- and sex-matched controls, Lorenz et 
al.40 demonstrated that HIV infection and HAART were in-
dependent risk factors for early carotid atherosclerosis. In 
the carotid bifurcation, the intima-media thickness values 
were 24.4% higher in HIV patients, and premature carotid 
lesions correlated with the use of combination antiretro-
viral therapy.
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A cross-sectional evaluation of HIV-positive participants 
and controls without pre-existing cardiovascular risk fac-
tors from the Fat Redistribution and Metabolic Change in 
HIV Infection (FRAM) study showed an increased preva-
lence of atherosclerosis measured by the intima-media 
thickness in HIV-positive subgroup, even after adjustment 
for traditional risk factors41. 
The association of HIV infection and cumulative expo-
sure to HAART with the presence of subclinical coro-
nary atherosclerosis was investigated by assessing the 
presence and extent of coronary artery calcification in a 
cross-sectional study of 947 male (332 HIV-negative and 
615 HIV-positive) participants from the Multicenter AIDS 
Cohort Study. After adjustment for age, race, family his-
tory, smoking, hypertension, HDL and LDL cholesterol lev-
els, both HIV infection and long-term HAART use were 
associated with a higher prevalence of coronary artery 
calcification. However, the extent of calcification was sig-
nificantly reduced among HAART users compared with 
HIV-negative controls42.
In a cross-sectional study including 130 HIV-infected pa-
tients receiving HAART, treatment for 2 or more years with 
a PI-based regimen compared to an NNRTI-based combi-
nation was associated with a greater carotid intima-media 
thickness43. Another case-control study of 77 HIV-infected 
men and 52 controls showed that HIV infection was inde-
pendently associated with increased carotid intima-media 
thickness and arterial stiffness, while antiretroviral treat-
ment was associated only with increased stiffness of the 
femoral artery44. 
In a recent report by McComsey et al.45, a greater preva-
lence of carotid atherosclerotic lesions was found also in 
HIV-infected children treated with antiretroviral therapy. 
Higher levels of carotid intima-media thickness and some 
cardiac markers (such as HOMA-IR, waist-to-hip ratio, cho-
lesterol and triglycerides), were found in 31 HIV-positive 
children receiving HAART when compared to 31 matched 
HIV-negative controls. These results are certainly worrying, 
because they suggest that HIV-infected children receiving 
antiretroviral therapy may be at increased risk of cardio-
vascular complications.
In contrast to the above studies, other published inves-
tigations have failed to find a direct effect on the arte-
rial wall of antiretroviral therapy. Depairon et al.46 studied 
168 HIV-infected persons, 136 of whom had received PIs. 
The prevalence of plaque lesions in the carotid or femo-
ral arteries was significantly higher in HIV-positive group 
in comparison with HIV-negative individuals (55% versus 
38%), but PI treatment did not independently predict vas-
cular lesions, whereas traditional risk factors (including 
age, male gender, cholesterol levels, and smoking), were 
associated with premature atherosclerosis. Talwani et 
al.47 showed that the rate of coronary atherosclerosis as-
sessed by coronary artery calcium among 60 HIV-infected 
patients was not associated with short-term antiretroviral 
therapy with or without PIs. Hsue et al.48 reported also 
a significantly higher rate of intima media thickness pro-
gression over one year in 121 HIV-positive subjects versus 
27 HIV-negative controls, but in this study PI therapy did 
not correlate with atheromatous plaques. Mercié et al.49 
noted that conventional risk factors were major determi-
nants of intima-media thickness evolution and premature 
atherosclerosis was not associated with type or duration 
of HAART among 346 HIV-positive subjects in a 12-month 
prospective cohort study.
These findings were corroborated by Currier et al.50 in 
a prospective matched cohort study involving 134 HIV-
infected and uninfected individuals, who underwent an 
ultrasonographic evaluation of the intima media thickness 
of the carotid artery. No association was found between PI 
exposure or HIV infection and carotid lesions, while signif-
icant predictors of higher carotid intima media thickness 
in a multivariate model included HDL cholesterol, triglyc-
erides, age, and body mass index. 
Mangili et al.51 performed a cross-sectional analysis of 
242 men and 85 women with HIV infection and found a 
more elevated prevalence of abnormal surrogate markers 
of cardiovascular risk (such as waist circumference, blood 
pressure, high-sensitivity C-reactive protein and body 
mass index). However, HAART administration was not as-
sociated with abnormal surrogate markers and increased 
risk of coronary heart disease. A recent study by Lebech et 
al.52 involving 25 non-smoking HIV-positive persons, has 
found no sign of accelerated atherosclerosis by evaluation 
of carotid artery intima-media thickness, and premature 
carotid lesions correlated with HDL cholesterol but not 
LDL cholesterol. Traditional risk factors for cardiovascular 
diseases did overshadow the role of HAART in other stud-
ies53,54, and a low CD4+ T-cell count was found to be the 
most robust risk factor for increased intima-media thick-
ness in HIV-positive patients by Kaplan et al.54.
In a recent cross-sectional study, Hsue et al.55 measured 
carotid intima-media thickness in 494 patients, including 
93 HIV-negative controls and 401 HIV-positive patients. 
HIV-positive group included patients treated with HAART 
and patients naïve to HAART with detectable or undetect-
able plasma HIV RNA. Premature atherosclerosis was as-
sociated with presence of HIV infection rather than viral 
load or CD4+ T cell count, and with antiretroviral drug 
exposure. This study showed that carotid intima-media 
thickness was higher among all groups of HIV-positive 
subjects compared to uninfected persons, irrespective of 
antiretroviral therapy or the level of viremia. 
A recent systematic review evaluated the evidence for 
subclinical atherosclerosis among HIV-positive patients 
from six cross-sectional, seven case-control, and 13 cohort 
studies including 5,456 HIV-infected and 3,600 HIV-unin-
fected patients. Subclinical atherosclerosis was diagnosed 
by ultrasonographic evaluation of carotid intima-media 
thickness, focal plaque incidence, or coronary artery cal-
cium detection. The weighted mean carotid intima-media 
thickness was 0.04 mm thicker among HIV-positive pa-
tients versus HIV-negative ones, and HIV infection was not 
associated with carotid plaques or presence of coronary 
calcium. Similarly, PI exposure did not significantly affect 
carotid intima-media thickness, carotid plaques, or coro-
nary artery calcium. These authors concluded that HIV in-
fection and PI therapy are not strong independent risk fac-
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tors for subclinical atherosclerosis, and that confounding 
may contribute to over-estimation of the risk associated 
with HIV seropositivity and PI exposure56.
In conclusion, the real impact of HIV infection and antiret-
roviral therapy on the development of subclinical athero-
sclerosis is still incompletely understood, even though 
most studies seem demonstrate in this population prema-
ture atherosclerosis and increased intima-media thickness. 
Similarly, the full clinical implications of surrogate mark-
ers of premature vascular lesions (including biochemical 
factors and vascular imaging findings), have not been 
completely evaluated. The contradictory findings in exist-
ing research are likely related to different study designs or 
populations, limitations of observational methods to con-
trol confounding factors, limited follow-up periods, differ-
ent methods of atherosclerosis evaluation, and frequent 
absence of HIV-seronegative controls.
The most important reports evaluating the association of 
HIV infection and PIs with accelerated atherosclerosis are 
summarized in Table 2.
Authors, years 
[references]
Type of 
study Outcome
N. of HIV-
positive 
patients
N. of HIV-
negative 
patients
Association 
with HIV 
infection
Association 
with PIs
Traditional risk factors associated with 
premature atherosclerosis
Lai, 2003 [34] P CAC 98 - - Yes Total and LDL cholesterol
Maggi, 2004 [11, 35] CS CIMT 293 - - Yes Age, smoking, CD4 cell count
Jericò, 2006 [12] CS CIMT 132 - - Yes Age, hypertension, hyperlipidaemia
De Saint Martin, 2006 
[39] CS CIMT 154 - - Yes Age, hypertension, triglycerides
Lorenz, 2008 [40] CS CIMT 292 1168 Yes Yes Age, body mass index, smoking, hypertension
Kingsley, 2008 [42] CS CAC 615 332 Yes
Yes
(HAART)
Age, smoking, race, family history, insulin 
resistance, hyperlipidaemia
Sankatsing, 2009 [43] CS CIMT 130 - - Yes Framingham risk, body mass index, HDL cholesterol
van Vonderen, 2009 
[44] CS CIMT 77 52 Yes No Age, smoking, hyperlipidaemia
Depairon 2001 [46] CS CIMT 168 68 Yes No Smoking, hyperlipidaemia
Talwani, 2002 [47] CS CAC 60 180 No No Smoking
Hsue, 2004 [48] CS IMT 148 63 Yes No
Age, smoking, hypertension, race, LDL 
cholesterol, 
low CD4 cell count
Mercié, 2005 [49] P CIMT 346 - - No Age, sex, smoking 
Currier, 2005 [50] P CIMT 88 44 No No Age, body mass index, triglycerides, HDL cholesterol
Mangili, 2006 [51] CS CIMT 327 - - No Age, body mass index, hypertension, high C-reactive protein
Lebech, 2007 [52] CS CIMT 25 14 No No HDL cholesterol
Bongiovanni, 2008 [53] P CIMT 186 54 No No Age, body mass index, triglycerides, glucose, high homocysteine
Kaplan, 2008 [54] P CIMT 1931 859 No No Age, smoking, hyperlipidaemia, low CD4 cell count
Hsue, 2009 [55] CS CIMT 401 93 Yes Yes
Age, smoking, LDL cholesterol, 
triglycerides, lipid lowering therapy, glucose, 
hypertension, high C-reactive protein
HIV, human immunodeficiency virus; PIs, protease inhibitors; P, prospective; CS, cross-sectional; CAC, coronary artery calcification; CIMT, carotid intima media thickness; LDL, low-
density lipoprotein; HDL, high-density lipoprotein; HAART, highly active antiretroviral therapy.
Table 2. Cross-sectional and prospective studies evaluating the association of premature atherosclerosis with HIV infection, antiretroviral 
therapy, and traditional risk factors
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The role of hiv infection
Recent data support the hypothesis that both HIV infec-
tion and antiretroviral treatment promote atherosclero-
sis and its clinical manifestations through inflammatory 
mechanisms involving arterial wall and endothelial cells, 
either directly or indirectly, also by the metabolic altera-
tions they induce57,58.
During the last decades, inflammation was demonstrated 
to play a major role during all stages of atherosclerosis, 
and the incidence of cardiovascular diseases was found 
to be increased in patients with chronic inflammatory dis-
eases, such as systemic lupus erythematosus, rheumatoid 
arthritis, Sjögren’s disease, and vasculitis59,60. In general, 
activation of leucocytes and increased concentrations of 
cytokines and other inflammatory mediators associated 
with exacerbations of inflammatory disorders may pro-
duce detrimental effects on the arterial wall. Particularly, 
atherogenic effects of a systemic inflammation can mani-
fest at three different levels: (1) endothelial dysfunction; 
(2) secondary dyslipidaemia; (3) activation of the coagula-
tion cascade60. 
If an inflammation systemic state participates pivotally in 
all stages of atherosclerosis, from fatty streak formation up 
to plaque progression and destabilization, soluble biologi-
cal markers of inflammation should provide independent 
diagnostic and prognostic value by reflecting and underly-
ing the disease state. Recent studies suggest that several 
inflammatory biomarkers such as C-reactive protein (CRP), 
fibrinogen, secretory phospholipase A2, interleukin (IL)-1, 
IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), 
soluble CD40 ligand, E-selectin, P-selectin, matrix metal-
loproteinases (MMPs), myeloperoxidase (MPO), tumor 
necrosis factor-α (TNF-α), intercellular adhesion molecule-1 
(ICAM-1), and vascular adhesion molecule-1 (VCAM-1) 
may have a potential role for the prediction of risk for 
developing coronary artery disease and may correlate with 
severity and mortality of atherosclerotic disease, also in 
HIV-positive subjects61-63. Although the circulating concen-
tration of these inflammatory biomarkers usually correlate 
with increased cardiovascular risk in general population, 
few are ready for clinical practice with the exception of 
CRP, which strongly and independently predicts adverse 
cardiovascular events64. 
In conjunction with the above-mentioned general effects 
of systemic inflammation, there are additional patho-
logic mechanisms anchored within the pathophysiology 
of  individual inflammatory diseases that are specific to 
that particular disorder, such as HIV infection. Numerous 
mechanism exist as to how HIV can directly damage en-
dothelium, which is continuosly exposed to a number of 
viral-induced trigger, including HIV-infected cells, freely 
circulating HIV virions, HIV proteins released upon host 
cell lysis, actively secreted viral proteins, and viral-induced 
proinflammatory cytokines.
Endothelial cells have been shown to be variably permissive 
for HIV infection. HIV itself is able to penetrate coronary 
artery and brain microvascular endothelial cell membrane, 
and to initiate inflammatory and biochemical intracellular 
reactions. Endothelial activation may also occur either by 
cytokines secreted in response to mononuclear or adven-
titial cell activation by HIV virus, or by the effects of gp120 
and Tat, two secretory HIV-associated proteins65,66.
The activation of endothelium induced by either HIV infec-
tion itself or by a leucocyte-mediated inflammatory cas-
cade triggered by the same virus leads to the increased ex-
pression of endothelial cellular adhesion molecules, such 
as ICAM-1, VCAM-1, E-selectin, P-selectin, thrombomod-
ulin, tissue plasminogen activator (tPA), and plasminogen 
activator inhibitor 1 (PAI-1)67,68.  
HIV-infected antiretroviral-naïve patients display mark-
ers of endothelial activation.  Increased serum levels of 
ICAM-1, VCAM-1, E-selectin, von Willebrand factor, PAI-
1, and thrombomodulin were demonstrated in patients 
with advanced HIV infection and opportunistic diseases, 
and higher levels of these markers were found in these 
patients compared with healthy controls. Moreover, solu-
ble markers of endothelial dysfunction  positively corre-
late with anti-p24 antibody levels, reduction of CD4 lym-
phocyte count, and disease severity69-71. This up-regula-
tion of cell adhesion and endothelial activation molecules 
in HIV-positive patients naïve to antiretroviral treatment 
suggests that the virus activates and dysregulates en-
dothelial cells.
Experimental evidence show that HIV-1 proteins affect the 
endothelium in both specific and overlapping ways. Tat 
protein is the principal transactivator for HIV-1 replication, 
is actively secreted by infected cells, and is probably in-
volved in HIV-induced endothelial dysfunction. Low con-
centrations of Tat protein significantly impair endothelium-
dependent vasorelaxation in isolated pig coronary arteries 
without affecting smooth muscle cell function72. In vitro 
and in vivo studies have shown that endothelial cells of 
diverse origin (umbilical vein, pulmonary artery, aorta, and 
brain) release MCP-1 and induce expression of VCAM-1 in 
response to Tat73,74. Finally, Tat interacts with three known 
receptors to gain access to endothelium: the integrins α5β3 
and α5β1 through Tat’s Arg-Gly-Asp (RGD) motif, and the 
vascular endothelial growth factor receptor-2 (VEGFR-2) 
through Tat’s basic domain. Activation of these receptors 
initiates endothelial signal transduction cascades regulat-
ing several processes such as cytoskeletal dynamics, en-
dothelial permeability, MMP activation, chemotaxis, and 
apoptosis. Particularly, Tat-mediated activation of p21-
activated kinase-1 (PAK-1) increases endothelial oxidative 
stress through NADPH oxidase activation and through de-
creased antioxidant capacity75. 
Similarly to Tat, gp120 glycoprotein induces the expres-
sion of ICAM-1 in human coronary artery, lung, brain, 
umbilical vein, and dermal microvascular endothelial cells, 
and significantly increases the adhesion of monocytes and 
lymphocytes to the endothelium76,77. Furthermore, gp120 
promotes apoptosis in human coronary endothelial cells, 
and negatively affects endothelial function through the 
production of potent vasoconstrictors, such as endothe-
lin-1. Like Tat, reactive oxygen species (ROS) have also 
implicated in gp120-induced toxicity of endothelium, and 
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the molecular mechanism by which gp120 exerts its en-
dothelial damage may involve protein kinase C and p38 
mitogen-activated protein kinase signaling78-80. Moreover, 
recent data show that gp120 activates signal transducers 
and activators of transcription (STAT) pathway, and induc-
es IL-6 and IL-8 secretion in human brain microvascular 
endothelial cells81.
The effects of other HIV-1 accessory proteins on en-
dothelial cell biology, are considerably less well-known. 
In vitro data suggest that Nef alters vascular homeostasis 
by affecting endothelial cells and macrophages through 
distinct pathways. Enhanced Nef-mediated macrophage 
activation and superoxide generation may contribute to 
vascular dysfunction, but Nef probably plays an additional 
role by altering cholesterol metabolism. In particular, Nef 
increases cholesterol biosynthesis, binds to newly creat-
ed cholesterol in order to enrich lipid rafts at the plasma 
membrane, and favours the macrophage transformation 
into a lipid-loaded foam cell82,83. Vpu seems up-regulate 
the tumor necrosis factor receptor family molecule CD40, 
inducing VCAM-1 expression and adhesion of B-lympho-
ma cells to the endothelium84.
Endothelial dysfunction is also associated with an in-
crease in oxidative stress, and ROS play an important role 
in dysregulating the endothelium by oxidatively damag-
ing cellular macromolecules, inactivating enzymatic sys-
tems, and altering transcription factor activation85. Multi-
ple cell types of arterial wall may produce ROS, including 
activated macrophages, T lymphocytes, vascular smooth 
muscle cells, and endothelial cells. HIV infection is associ-
ated with increased free radical production and chronic 
oxidative stress, suggesting a role for ROS in HIV-induced 
endothelial damage. In fact, elevated ROS levels have also 
been reported in peripheral blood monocytes from HIV-
infected subjects, and antioxidant restoration via dietary 
supplements improves cardiovascular health in HIV-posi-
tive patients86,87.  
The HIV-induced endothelial dysfunction is clinically dem-
onstrated by some studies assessing the flow-mediated 
dilatation (FMD) of the brachial artery, which is often used 
as an indicator of endothelial function in humans. Blum 
et al. evaluated brachial artery diameter in 24 HIV-positive 
subjects and found that HIV viral load correlated inversely 
with endothelial function88. Similarly, in a cross-section-
al analysis including 75 HIV-infected patients compared 
with 223 HIV-negative controls, a significant association 
between reduced brachial artery FMD and HIV viremia 
was found, particularly among injection drug users89. In 
conclusion, in these reports HIV-positive, HAART naïve in-
dividuals have significant impairment of endothelial func-
tion when compared with HIV-negative controls. 
The role of antiretroviral therapy
The ability of HAART to accelerate atherosclerosis and 
increase cardiovascular risk in HIV-positive subjects has 
been controversial in that some studies have found an as-
sociation and other studies have not found an association. 
Numerous mechanism exist as to how antiretroviral treat-
ment can protect or damage the vascular endothelium, as 
showed by experimental and clinical data, and the global 
effect is still unknown.
The remarkable decrease in viral replication and plasma 
HIV viral load induced by combination antiretroviral ther-
apy should improve T-cell function and reduce the HIV-
associated endothelial dysfunction. In fact, several authors 
have reported a significant decrease in serum concentra-
tions of VCAM-1 and ICAM-1 after the first months of 
HAART, suggesting that the reported reversion of en-
dothelial activation is mediated by control of viral replica-
tion obtained by potent antiretroviral treatment89,90. Simi-
larly, the SMART study showed that the risks for all-cause 
mortality (including mortality for cardiovascular diseases) 
were higher in participants randomized to treatment in-
terruption than in those who received continuous antiret-
roviral therapy29.
However, HAART may also indirectly or directly induce 
endothelial dysfunction. It has early been assumed that 
use of several antiretroviral agents (mostly PIs, stavudine, 
efavirenz) favours the occurrence of multiple metabolic 
and morphologic abnormalities, including dyslipidaemia, 
insulin resistance, diabetes mellitus, subcutaneous fat 
loss, visceral fat accumulation, and metabolic syndrome, 
which are associated with an increased risk of premature 
atherosclerosis and myocardial infarction. Lipid abnormali-
ties occur early in HIV infection, with reduction in HDL 
and LDL cholesterol and increase in triglycerides, but they 
became very common after the introduction of PI-based 
combination therapy91,92.
PI-related dyslipidaemia has been attributed to inhibition 
of lipid metabolism and adipocyte regulatory proteins 
that have partial homology to the catalytic site of HIV-
1 protease, to which PIs bind. These regulatory proteins 
include the cytoplasmic retinoic acid-binding protein type 
1 (CRABP-1), which is critical for maturation and prolifera-
tion of adipocytes, and the LDL-receptor related protein 
(LRP), an hepatic cell receptor which cleaves fatty acids 
from circulating triglycerides93,94. Several other pathoge-
netic mechanisms have been described: PIs could inhibit 
proteasomal degradation of nascent apolipoprotein B (the 
main protein component of triglycerides and cholesterol 
rich plasma lipoproteins), promote intracellular accumula-
tion of cholesterol in macrophages, induce foam cell for-
mation by an upregulation of CD36 in peripheral blood 
mononuclear cells, and alter the function of pre-existing 
adipocytes leading to hypertriglyceridaemia91,95,96. Human 
studies have suggested that PIs may decrease the function 
of lipoprotein lipase and reduce the clearance of very low 
density lipoprotein (VLDL)-triglycerides from plasma, pre-
venting the generation of new adipocytes, and severely 
limiting the function of existing adipocytes97.
The PI-induced metabolic disturbances may also are as-
sociated with a reduced secretion of adiponectin. Adi-
ponectin is an anti-diabetic and anti-inflammatory pro-
tein producted in adipose tissue, and its levels decrease in 
association with insulin resistance, obesity, and increased 
expression of endothelial adhesion molecules in the gen-
eral population. Preliminary data suggest that reduced 
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adiponectin concentrations may increase the risk of coro-
nary heart disease, event though this relationship has not 
been yet evaluated in HIV-positive subjects98. Recently, 
studies use 3T3-F442A cells and mice have found that 
HIV protease inhibitors decrease adiponectin mRNA levels 
and secretions99. 
Although several clinical studies have established that 
HAART promote endothelial dysfunction indirectly by in-
ducing lipid and glucose metabolism alterations, data ob-
tained from experimental investigations on animal models 
have also proved a direct effect of HAART on endothelial 
cells and function. 
The molecular mechanism of PI damage in endothelium 
has been described in detail, and many in vivo and  in 
vitro experiments suggest an oxidative stress in PI-related 
endothelial dysfunction. In fact, PIs reduce the excretion 
of urinary nitrate, a stable degradation product of nitric 
oxide, and decrease the expression of endothelial nitric 
oxide synthase. In addition to decrease in nitric oxide pro-
duction and impairment in endothelium-dependent va-
sodilatation capacity, PIs have been reported to increase 
superoxide production and subsequently oxidative stress. 
Moreover, PIs decrease mitochondrial membrane poten-
tial, increase mitochondrial production of ROS, increase 
endothelial cell permeability, and favour leukocyte adhe-
sion in cell culture models75,97,100. 
Clinical evidence for NRTI-induced vascular toxicity is dif-
ficult to assess because NRTIs are not prescribed as mono-
therapy. In vitro studies showing a direct endothelial toxicity 
related to NRTIs are not numerous, but some experimental 
evidences support a direct role for this class in endothelial 
dysfunction. In general, mitochondrial toxicity caused by 
nucleoside analogues is responsible for abnormal oxida-
tive phosphorylation, aberrant cellular respiration, and 
cellular toxicity also in endothelium75. Particularly, aortas 
from mice treated with zidovudine have a significant re-
duction in maximum endothelial-dependent relaxation, as 
well as a remarkable decrease in acetylcholine sensitivity. 
Most recent studies show that zidovudine increases aortic 
endothelium superoxide levels in animal models, implicat-
ing ROS in NRTI-related endothelial dysfunction101,102.
The recent association of the use of the nucleoside ana-
logue abacavir with an increased risk of myocardial infarc-
tion was investigated in several studies, in order to find 
plausible pathogenetic mechanisms. In the SMART study, 
serum high sensitivity CRP and IL-6 levels were significant-
ly higher for patients receiving abacavir, and a direct role 
of this drug in vascular inflammation was suggested32. 
Similar results were found in a cohort study including 61 
antiretroviral-treated patients with undetectable HIV RNA, 
which showed a significant lower flow-mediated dilata-
tion of the brachial artery in abacavir-treated subjects, as-
sociated with an impaired endothelial function103. Abacav-
ir has been shown to induce cardiomyopathy in mice and 
rats, and it is metabolised intracellularly to carbovir, which 
has the potential to be cytotoxic31,104. However, serum lev-
els of inflammatory markers (such as TNF-α, IL-6, IL-8, and 
MCP-1), did not significantly increase in 41 HIV-infected 
patients after 1 year of abacavir-based therapy105, and the 
biological mechanism of possible endothelial damage as-
sociated with abacavir is still unknown. 
Finally, a possible contribution of cell-mediated immune 
responses to the pathogenesis of the atherosclerosis asso-
ciated with HIV infection was also supposed. Post-ischae-
mic flow-mediated dilatation of the brachial artery was 
found to be significantly associated with percentage of 
“naïve” CD4+ 45RA+ T cells, while plasma lipid and insu-
lin concentrations did not correlate with endothelial func-
tion among 48 patients assessed by Nolan et al.106. On the 
other hand, increased carotid intima-media thickness was 
associated with depletion of circulating myeloid dendritic 
cells in 36 HIV-positive subjects on suppressive HAART107.
To conclude, antiretroviral therapy should reduce the 
endothelial damage by controlling HIV infection, but it 
would also induce endothelial dysfunction by a direct ef-
fect or by deranging both lipid and glucose metabolism. 
Further enlarged studies are certainly needed in order to 
better define this complex interaction between antiretro-
viral drugs and endothelium. 
Screening and assessment of cardiovascular risk
With an increase in cardiovascular disease rates and aging 
of HIV-infected patients, screening and appropriate as-
sessment of cardiovascular risk in this population assumes 
increasing importance. A founding element of preventing 
cardiovascular diseases is that the intensity of risk-reducing 
interventions should be based on the level of cardiovascu-
lar risk. Patients with established cardiovascular disease 
or high cardiovascular risk qualify for the most aggressive 
risk factor management, with special focus on strategies 
able to prevent myocardial infarction and death.
Insufficient data currently exist to recommend a screening 
strategy different from that for HIV-negative subjects, but 
currently available cardiovascular risk prediction equations 
were not developed and approved in HIV-positive adults 
and children. In the general population, presently avail-
able prediction models of coronary heart disease risk were 
derived from the Framingham Heart Study and estimate 
the risk for an initial coronary event in a population of 
middle-aged adults with minimal coronary heart disease 
risk at the beginning of the observation period108,109. 
To date, the estimates of the relative effects of traditional 
risk factors on cardiovascular outcomes appear simi-
lar between HIV- and non-HIV-infected individuals, and 
the Framingham coronary heart disease risk predictions 
have performed reasonably satisfactory when applied to 
HIV-positive population. However, specific cardiovascular 
risk factors were found in HIV-infected subjects, and the 
above-mentioned equations may not provide suitable pre-
dictions for young people living with HIV infection110. Par-
ticularly, HIV and antiretroviral therapy may directly and 
indirectly promote endothelial dysfunction, as discussed 
above, in association with metabolic disturbances and adi-
pose tissue redistribution. Moreover, HIV-positive persons 
are different in terms of both demographic characteris-
tics (younger and more racially diverse) and prevalence of 
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substance abuse (mostly tobacco and recreational drugs). 
At the same time, other medications, lifestyle/behavioural 
choices (diet, physical inactivity, alcoholism and substance 
abuse) may deeply affect the global cardiovascular risk in 
this population.
The Framingham risk equation includes age, sex, blood 
pressure, total cholesterol, HDL cholesterol, diabetes mel-
litus, and cigarette smoking to calculate a 10-year coro-
nary heart disease risk108. This algorithm has been applied 
to HIV-infected people and investigated in the DAD study 
and has been shown to perform reasonably well, although 
it somewhat underestimates cardiovascular risk111. 
New HIV-specific algorithms for prediction of coronary 
heart disease risk have recently proposed by the DAD 
investigators. The DAD-derived HIV-specific prediction 
models incorporated traditional risk factors (such as age, 
blood pressure, lipid profile, diabetes mellitus and smok-
ing) associated with exposure to antiretroviral agents, and 
captured cardiovascular events as the dependent vari-
able112-114. The Framingham equation predicted remark-
ably well the risk, but tended to underestimate coronary 
events in HIV-positive smokers and overestimate cardio-
vascular risk in non-smokers. Moreover, predicted rates of 
myocardial infarction increased in a parallel fashion with 
increased duration of combination antiretroviral therapy, 
suggesting that the observed increase in cardiovascular 
risk may at least in part be explained by HAART-induced 
changes in traditional risk factors112. Further external vali-
dation of the DAD prediction algorithm is warranted to 
assess whether it is applicable to people living with HIV 
infection. Larger, multicenter, prospective study including 
both traditional and HIV-specific risk factors are conse-
quently needed in order to determine the optimal specific 
algorithm to predict coronary heart disease risk in HIV-
positive population.
All HIV-infected patients should be carefully evaluated at 
their first clinical visit for categorical risk factors for coro-
nary events that are summarized in Table 3. Laboratory 
parameters for identifying alterations in lipid and glucose 
metabolism should include total cholesterol, LDL choles-
terol, HDL cholesterol, triglycerides, and glycaemia (ob-
tained after a minimun of eight hours of fasting). The lipid 
and glucose panel should be repeated every 3-4 months 
if patients are assuming stable antiretroviral treatment, or 
annually if patients are not being treated and have nor-
mal lipid and glucose values. For subjects with serum trig-
lyceride levels >200 mg/dL, the measurement of serum 
lipid profile should be repeated within 1-2 months after 
starting antiretroviral therapy. Risk factors more specific 
to HIV-positive patients should also be collected, including 
lifestyle (alcoholism, cocaine, and other psychotropic sub-
stances), drugs interfering with glucose and lipid metabo-
lism (such as growth hormone, estrogens, corticosteroids, 
thyroid hormones), body mass index, abdominal circum-
ference, duration and type of HAART, HIV viral load, nadir 
and CD4 lymphocyte count, and chronic hepatitis C115-117.
It is useful for an electrocardiogram to be performed at the 
beginning of HAART, while in patients with several cardio-
vascular risk factors or established cardiovascular disease 
a periodic electrocardiogram, an echocardiography, and a 
doppler-echographical examination of supra-aortic vascu-
lar trunk are advisable. In patients with basal glycaemia on 
an empty stomach above 100 mg/dL, insulinemia, HOMA 
test calculation, and oral glucose tolerance test (OGTT) 
should be performed117.
The number of categorical risk factors for coronary heart 
disease determines the target level of LDL cholesterol and 
the aggressiveness of lipid-lowering treatment. The pa-
tient’s absolute 10-year risk of myocardial infarction or 
cardiac death should be calculated using the Framingham 
risk factor calculator, which can be found at http://www.
nhlbi.nih.gov/guidelines/cholesterol/index.htm118,119. 
High-risk patients are subjects with established coronary 
heart disease or those with a coronary risk “equivalent”, 
such as cerebrovascular disease, peripheral vascular dis-
ease, diabetes mellitus, or two or more risk factors that 
predict a 10-year risk of myocardial infarction or cardiac 
death >20%. Moderate-risk patients are those with two 
or more risk factors but a 10-year risk <20%. Finally, low-
risk patients are those with 0 or 1 risk factor for coronary 
heart disease. 
Finally, newer inflammatory biomarkers, such as high-
sensitivity C-reactive protein (HS-CRP) and adiponectin, 
may proved useful also for identifying HIV-infected pa-
tients at risk for coronary heart disease, but to date the 
specificity of such markers for the assessment of coronary 
risk in HIV-positive subjects remains unclear. Although the 
Prevention/American Heart Association guidelines recom-
mend measuring of HS-CRP in HIV-negative patients at 
intermediate risk for cardiovascular diseases, this strategy 
requires validation in HIV-positive population in whom C-
reactive protein levels are frequently increased. Similarly, 
long-term data on the clinical significance of reduced adi-
ponectin level in HIV-positive subjects with fat redistribu-
tion syndrome are not available. Other surrogate markers 
for coronary heart disease, including intimal-medial thick-
ness, computed tomographic angiography, and coronary 
Risk factors Definition
Age
>45 years for men
>55 years for women
Family history of premature CHD
Male first-degree relative <55 years 
old or female first-degree relative 
<65 years old
Arterial hypertension
Blood pressure >140/90 mmHg, or 
receipt of antihypertensive treatment
Cigarette smoking -
Low HDL cholesterol* <40 mg/dL
CHD, coronary heart disease
* An elevated HDL cholesterol concentration (>60 mg/dL) is considered a “negative” 
risk factor and, if present, it subtracts one factor from the above-mentioned risk 
factor total.
Table 3. Categorical risk factors for coronary heart disease that 
determine the 10-year risk of myocardial infarction and the target 
levels of LDL cholesterol
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artery calcification have been investigated but not vali-
dated as independent predictors of coronary heart disease 
outcomes in HIV-infected population92. Future researches 
are certainly needed in order to determine the optimal 
screening strategy and risk stratification algorithm for HIV-
positive individuals, and to define sensitivity and specificity 
of new diagnostic tests for coronary disease, including in-
flammatory and surrogate markers.
Prevention strategies to reduce cardiovascular risk
As with HIV-negative persons, the most important princi-
ple to prevent cardiovascular diseases in HIV-positive pop-
ulation is that risk-reducing strategies should be based on 
the level of coronary heart disease risk and whether the 
presence of cardiovascular diseases has been established.
HIV-infected patients clearly have a significant risk of 
atherosclerosis given their underlying traditional risk fac-
tors. Early intervention to reduce these risks is recom-
mended in all HIV-infected patients and include smoking 
cessation, blood pressure management, weight loss, and 
correction of lipid and glucose metabolism abnormalities.
Prevalence of cigarette smoking is great among HIV-posi-
tive patients, ranging from 47% to 71%, and higher than 
in general population. Aside from a diagnosis of cardiovas-
cular disease, current cigarette smoking is the most pow-
erful predictor of cardiovascular events among individuals 
with HIV infection, and a significant reduction in cardio-
vascular risk and total mortality associated with smoking 
cessation has been demonstrated in non-HIV population. 
Preventing HIV-positive individuals (particularly educating 
teenagers) from starting smoking is critical, because stop-
ping smoking remains a very difficult challenge120.
Arterial hypertension is also a powerful predictor for cardi-
ovascular events in general population. The best evidence 
suggests that HAART may be associated with a modest in-
crease in blood pressure and prevalence of hypertension, 
that has not been established with certainty among HIV-
positive patients, but usually ranges from 12% to 20% 
among individuals <40 years old and from 35% to 41% 
among those >40 years old121,122. Among HIV-negative 
patients, dietary interventions are effective for reducing 
blood pressure, and one study showed also that HIV-pos-
itive patients who completed an intensive lifestyle inter-
vention that included dietary changes and regular physical 
activity experienced a significant reduction in blood pres-
sure values. Drug therapy for hypertension significantly 
decreases cardiovascular risk in general population, but 
specific researches are needed in order to evaluate phar-
macodinamic interactions between commonly used anti-
hypertensive agents and antiretroviral drugs, owing to the 
overlap in metabolic pathways affected by antiretroviral 
agents (mostly PIs and NNRTIs) and certain antihyperten-
sive drugs123.    
The Infectious Disease Society of America (IDSA) and 
Adult AIDS Clinical Trials Group (AACTG) have updated 
specific guidelines for evaluation and management of 
HAART-related hyperlipidaemia116. These recommenda-
tions are based on those provided by the National Choles-
terol Education Program Adult Treatment Panel III (NCEP 
ATP III) guidelines, which adjust the intensity of risk reduc-
tion therapy to the patient’s risk of developing an acute 
coronary event118,119.
Except for subjects with triglycerides >500 mg/dL, in 
whom the primary goal is to reduce triglyceride concen-
tration and prevent pancreatitis, the primary target is re-
duction of LDL cholesterol levels. Lipid goals and cutoffs 
for lifestyle modification and drug therapy are summa-
rized in Table 4. When patients have triglycerides >200 
mg/dL, the cholesterol content of triglyceride-rich lipopro-
teins is increased and the estimated LDL-cholesterol un-
derestimates the number of atherogenic particles. In this 
case, non-HDL cholesterol (calculated as total cholesterol 
minus HDL cholesterol) becomes the secondary target of 
medical intervention; the non-HDL cholesterol goals are 
simply the LDL cholesterol goals plus 30 mg/dL. It is very 
important to consider the non-HDL cholesterol concentra-
tion or its mathematical equivalent (the total cholesterol/
HDL cholesterol ratio) when assessing hyperlipidaemia in 
HIV-infected patients, because such individuals frequently 
have hypertriglyceridaemia or mixed hyperlipidaemia, and 
the LDL cholesterol concentrations usually underestimate 
the overall atherogenic lipoprotein burden116-119.
Treatment of HAART-associated dyslipidaemia includes 
three levels of medical intervention: lifestyle changes and 
diet therapy, modification of current antiretroviral regi-
men, and lipid-lowering drugs.
Non-drug therapies should generally be instituted first 
and given a thorough trial before starting drug therapies. 
Apart from stopping smoking, patients with HIV infec-
tion and receiving antiretroviral therapy should regularly 
perform moderate aerobic activity for a minimum of 30 
minutes five times per week, with a goal of 60 minutes, to 
Risk category LDL-C goal
Initiate 
TLC
Consider 
drug 
therapy
High risk: CHD or CHD 
equivalents1 
(10-year risk >20%)
<100 mg/dL
(optional goal: 
<70 mg/dL)
>100 
mg/dL
>100 mg/dL
Moderately high risk: >2 
risk factors2
(10-year risk 10% to 20%)
<130 mg/dL
>130 
mg/dL
>130 mg/dL
Moderate risk: >2 risk 
factors2
(10-year risk <10%)
<130 mg/dL
>130 
mg/dL
>160 mg/dL
Low risk: 0-1 risk factor2 <160 mg/dL
>160 
mg/dL
>190 mg/dL
Table 4. ATP III LDL-cholesterol goals and cutpoints for therapeutic 
lifestyle changes and lipid-lowering therapy in different risk 
categories [118, 119].
LDL-C, low-density lipoprotein cholesterol; TLC, therapeutic lifestyle changes; CHD, 
coronary heart disease.
(1)CHD includes history of myocardial infarction, unstable angina, stable angina, 
coronary artery procedures, or evidence of clinically significant myocardial 
ischemia; CHD equivalents include clinical manifestations of noncoronary forms of 
atherosclerotic disease, diabetes, and 2 or more risk factors with 10-year risk for 
hard CHD >20%.
(2)Risk factors include: cigarette smoking, hypertension (blood pressure >140/90 mm 
Hg or on antihypertensive medication), low high-density lipoprotein (HDL) cholesterol 
(<40 mg/dL), family history of premature CHD, and age (men >45 years, women 
>55 years).
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be carried out 5 to 7 times per week. This routine physical 
exercise usually improves trunk adiposity and plasma lipid 
parameters, and might therefore be beneficial to reduce 
cardiovascular disease risk. At the same time, patients 
who are overweight should also restrict calories to achieve 
their ideal body weight. Improvement of cardiovascular 
outcomes has been associated with substitution of non-
hydrogenated unsaturated fats for saturated fats and 
trans-fats, increased intake of omega-3 fats from fish, fish 
oil, or plants, and eating a diet that is high in fruits, veg-
etables, nuts, and whole grains but low in refined grains. 
Dietary and exercise intervention resulted in a significant 
11-25% decrease in total cholesterol and triglyceride lev-
els in HIV-infected patients116,124.
Several studies have showed that an antiretroviral regimen 
in which a PI is replaced with nevirapine or abacavir in pa-
tients with long-lasting viral suppression usually maintains 
optimal antiviral acitivity. Moreover, as compared with PIs, 
these agents reduce serum lipid abnormalities, offer more 
convenient dosing regimens, involve fewer pills, and re-
sult in fewer potentially serious drug-drug interactions, re-
duced side effects, and improved adherence to antiretro-
viral therapy. However, the rate of virological failure might 
eventually increase among patients who have previously 
received prolonged non-suppressive antiretroviral treat-
ment, such as single or dual NRTI therapy, as a result of 
the re-emergence of archived viral resistance. Significant 
improvement in serum lipid concentrations was also re-
ported after switching from stavudine or zidovudine to 
abacavir or tenofovir, or after replacing current PI with 
atazanavir, an azapeptide PI which is usually associated 
with a more favourable plasma lipid profile125-127.
Lipid-lowering therapy becomes suitable when lifestyle 
modifications, dietary changes, physical activity, and 
switching treatment are ineffective or not applicable, and 
for patients with urgent need of drug intervention (such 
as those with coronary heart disease or equivalent, and 
those with extreme elevation in serum lipid levels). Drug 
therapy for dyslipidaemia in HIV-infected patients receiv-
ing HAART is problematic, because of potential drug in-
teractions, toxicity, intolerance, and reduced patient ad-
herence to multiple pharmacologic regimens.
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-Co A) 
reductase inhibitors, or statins, are considered the current 
first-line therapy for primary hypercholesterolaemia. Most 
of these compounds are metabolized by the cytochrome 
P450 3A4 and may cause clinically relevant interactions 
with other agents that are changed by this enzymatic 
complex, such as PIs and NNRTIs. Simvastatin, lovastatin, 
and atorvastatin are extensively metabolized by CYP 3A4: 
these notable drug interactions cause elevated plasma lev-
els of statins, leading to a significantly increased risk of 
liver and skeletal muscle toxicity (acute hepatitis, myopa-
thy and rhabdomyolysis). On the other hand, fluvastatin 
is metabolized by CYP 2C9 and pravastatin is not signifi-
cantly metabolized by the CYP enzyme system, with a very 
low risk of drug interactions.
Consequently, it is reasonable to recommend the use of 
pravastatin (20-40 mg daily starting dose) or atorvasta-
tin (10 mg daily starting dose) as first-line treatment for 
hypercholesterolaemia in PI-treated patients, and the use 
of fluvastatin (20-40 mg starting dose), as second-line 
regimen. On the other hand, simvastatin and lovastatin 
should be avoided, because they present a great risk of 
pharmacological interactions with PIs128,129.
Rosuvastatin is a new HMG-Co A reductase inhibitor that 
showed the highest dose-to-dose potency in lowering to-
tal and LDL cholesterol levels, compared with other cur-
rently available statins. Moreover, pharmacokinetic stud-
ies have demonstrated that its metabolism is not depend-
ent on the cytochrome P450 3A4 isoenzyme, and its use 
could be considered in PI-treated individuals as a result of 
the low risk of drug-drug interactions130. In a small, obser-
vational, pilot study involving 16 HAART-treated patients 
with hypercholesterolaemia, a 24-week treatment with 10 
mg daily of rosuvastatin reduced significantly total cho-
lesterol and triglyceride levels and was associated with a 
favourable tolerability profile131.
However, recent results showed a significant increase in 
rosuvastatin plasma levels in HIV-negative and HIV-positive 
subjects who are being treated with lopinavir/ritonavir, 
while the PI levels were not affected by the lipid-lowering 
drug. Therefore, the combination of rosuvastatin and lopi-
navir-ritonavir should be used with caution (at the lowest 
dosage of rosuvastatin) until safety and efficacy of this 
treatment have been confirmed in further studies132,133. 
Fibrates represent the cornerstone of drug therapy for 
hypertriglyceridaemia and mixed hyperlipidaemia. These 
compounds are also metabolized by hepatic cytochrome 
P450 enzymes, but they appear to primarly affect only 
CYP 4A, and do not show clinically rilevant interactions 
with PIs. However, concomitant use of both fibrates and 
statins can increase the risk of skeletal muscle toxicity and 
should be avoided. Treatment with gemfibrozil (600 mg 
twice daily), bezafibrate (400 mg daily), or fenofibrate 
(200 mg daily), generally results in a significant reduction 
in serum triglyceride and cholesterol levels in HIV-infected 
patients receiving a PI-containing therapy, with a more 
evident improvement of hypertriglyceridaemia133,134.
Second-line lipid-lowering agents include fish oils in pa-
tients with hypertriglyceridaemia, ezetimibe in those with 
increased LDL-cholesterol levels, and niacin in those with 
mixed hyperlipidaemia. However, these compounds have 
not yet been studied in detail in HIV infected patients. 
Moreover, niacin and ezetimibe require monitoring of he-
patic transaminases, and niacin may be associated with 
hyperglycaemia, hyperuraemia, and skin rash116. Recom-
mendations for choice of initial drug therapy for dyslipi-
daemia are listed in Table 5. 
Prevalence of impaired fasting glucose (defined as fasting 
blood glucose > 100 mg/dL), and impaired glucose toler-
ance (defined as a 2-hour glucose >140 mg/dL after a 75-g 
glucose load), is increased in patients with HIV infection 
and higher in those exposed to HAART135,136. The initial 
management approach for the HAART-related hyperg-
lycaemia includes increased physical exercise and dietary 
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therapy. If diet and physical activity fail to achieve the de-
sired level of glucose (defined by fasting glucose concen-
trations <126 mg/dL or random levels <200 mg/dL) after 
eight weeks, patient should be sent to a diabetes specialist 
and pharmacologic therapy should be considered. 
Since alterations in glucose metabolism associated with 
HAART resemble those seen in type 2 diabetes mellitus, 
drug therapy in HIV-positive patients with hyperglycae-
mia should be that recommended for type 2 diabetes 
and started with an oral hypoglycaemic agent, which 
may reduce glycaemia and improve insulin sensitivity. 
However, there are very few data about efficacy and 
safety of these medications in HIV-positive patients, but 
the insulin-sensitizing compounds seem to be preferable 
because they can ameliorate insulin resistance and vis-
ceral fat accumulation.
Metformin was generally well tolerated and only mild gas-
trointestinal adverse effects were rarely observed. Since 
this biguanide is not metabolized by the liver, there are 
no risks of drug interactions with PIs, but it should be em-
ployed with caution in patients receiving NRTIs, because 
of the increased risk of mitochondrial toxicity and lactic 
acidosis. However, at least over three months, metformin 
did not result in any increase of transaminase or lactic acid 
levels in recent trials137,138, even though metformin may se-
riously enhance the risk of lipoatrophy in such patients139.
The insulin-sensitizing compounds thiazolidinediones have 
been shown to improve insulin sensitivity and hypergly-
caemia in patients with type 2 diabetes, and also promote 
adipocyte differentiation in vitro. They have obtained 
promising results because of their potential to ameliorate 
insulin resistance, decrease visceral adiposity, and increase 
subcutaneous adipose tissue. On the other hand, in a re-
cent randomized, placebo-controlled trial, rosiglitazone 
did not produce significant changes in body fat compo-
sition, although seemed to ameliorate insulin resistance 
and decrease live fat content140,141. However, rosiglitazone 
appeared to have some detrimental effects on lipid pro-
files129. The major cytochrome P450 3A4 isoenzymes are 
involved in the hepatic metabolism of pioglitazone, which 
is associated with the risk of potential drug interactions 
with other drugs metabolized by CYP 3A4 (such as PIs). 
Rosiglitazone, in contrast, is mostly metabolized by CYP 
2C8 and presents lower risks of drug-drug interactions. 
However, little is known about its pharmacological inter-
actions with antiretroviral drugs, and treatment with 4 mg 
daily of rosiglitazone has been associated with a reduced 
bioavailability of nevirapine142.
If fasting plasma glucose level of <126 mg/dL are not 
achieved with oral antidiabetic monotherapy, oral com-
bination treatment consisting of a sulfonylurea with met-
formin or rosiglitazone should be considered. Finally, in 
subjects who are severly hyperglycaemic at baseline (fast-
ing glycaemia >300 mg/dL), or who are symptomatic, 
insulin therapy alone or in combination with an oral hy-
poglycaemic agent (such as metformin or rosiglitazone) 
should be prescribed143.
Lipid alterations
First choice therapy
(rating)
Alternatives
(rating)
Elevated LDL cholesterol 
or elevated non-
HDL cholesterol with 
triglyceride level of 
200-500 mg/dL
Statin (B1):
- pravastatin, 20-40 mg daily
- atorvastatin, 10 mg daily
- fluvastatin, 20-40 mg daily
Fibrate (C1) 
or niacin (C3)
Triglyceride level > 500 
mg/dL
Fibrate (B1):
- gemfibrozil, 1200 mg daily
- fenofibrate, 200 mg daily
- bezafibrate, 400 mg daily
Niacin (C3) or 
fish oils (C3)
Table 5. Recommendations for choice of initial pharmacologic treat-
ment for hyperlipidaemia in HIV-infected patients receiving HAART
Ratings: 
-  strength of recommendation: B, moderate evidence to support a recommendation; 
C, poor evidence to support a recommendation; 
-  quality of evidence: 1, evidence from >1 properly randomized controlled trials; 2, evi-
dence from >1 well-designed clinical trials without randomization, case-controlled 
analytic studies, or multiple case-series;  3, evidence from opinion of respected au-
thorities [116].
Hypothetic pathogenetic mechanisms of HIV-induced endothelial dysfunction which 
may lead to inflammatory alterations of endothelium and premature atherosclerosis 
(IL-6, interleukin-6; IL-8, interleukin-8; STAT, signal transducers and activators of trans-
cription; PAK-1, p21-activated kinase-1; PKC, protein kinase C; ROS, reactive oxygen 
species; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular adhesion mole-
cule-1; tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor 1).
Figure 1
Possible protective and detrimental effects of antiretroviral therapy on endothelial cells 
(HAART, highly active antiretroviral therapy; ICAM-1, intercellular adhesion molecule-1; 
VCAM-1, vascular adhesion molecule-1; NO, nitric oxide; ROS, reactive oxygen species).
Figure 2
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he use of combination antiretroviral ther-
apy has converted HIV infection into a 
chronic disease, leading to the progressive 
occurrence of several comorbidities, such as atherosclero-
sis and coronary heart disese. Atherosclerosis in HIV-pos-
itive subjects is clearly multifactorial in origin, and ensues 
from traditional cardiac risk factors, HIV itself, and antiret-
roviral therapy. However, the absolute risk of cardiovascu-
lar events among HIV-infected subjects remains low and 
must be balanced against the remarkable benefits from 
HAART in terms of improvement in immune function and 
related morbidity and mortality.
Nonetheless, as HIV-infected patients live longer on new 
potent antiretroviral combinations, cardiovascular events 
could become increasingly frequent and cardiovascular 
risk evaluation should be performed regularly in these 
subjects, especially after initiation or change of antiretro-
viral regimen.  
Lifestyle modification strategies (including cigarette smok-
ing cessation, dietary changes, and regular exercise), 
should be rigorously encouraged, obtaining frequently a 
significant improvement in lipid and glucose metabolism 
abnormalities and reducing cardiovascular disease risk. 
Moreover, the choice of antiretroviral agents with a less 
detrimental effect on lipid and glucose profile should be 
considered in subjects with cardiovascular risk factors.. 
Pharmacological treatment of dyslipidaemia (usually with 
statins or fibrates) and diabetes (with biguanides or thiazo-
lidinediones), becomes mandatory when lifestyle changes 
and switching therapy are ineffective or not applicable, 
and when increases in lipid and glucose concentrations 
are severe or persist for a long time. However, preliminary 
guidelines regarding pharmacological therapy of metabol-
ic alterations associated with HAART can be made from a 
limited number of studies. Moreover, the benefit of ag-
gressive management of hyperlipidaemia and diabetes 
must be balanced with the risk of additional medications, 
potential drug interactions, additional pill burden, com-
promise in patient adherence, and potential compromise 
of optimal HIV infection control.
Maintaining virological suppression should be considered 
still today the main concern in HIV-infected patients treat-
ed with HAART, because short-term rates of cardiovascular 
complications remain quite low and are significantly lower 
than death rates for AIDS-related conditions in subjects 
with virological failure and immunological impairement. 
However, HIV and HAART should be routinely considered 
among the more traditional risk factors in assessing a pa-
tient for coronary heart disease, and a more aggressive 
intervention to reduce cardiac risk factors in persons with 
HIV infection is today mandatory. 
Further, enlarged, prospective studies are certainly needed 
in order to better evaluate the cardiovascular disease risk 
in HIV-positive individuals receiving HAART, and to define 
specific guidelines for the management of HAART-related 
metabolic abnormalities.
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